Genital Herpes Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Genital Herpes pipeline constitutes 26+ key companies continuously working towards developing 28+ Genital Herpes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Genital Herpes Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Genital Herpes Market.

The Genital Herpes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Genital Herpes Pipeline Report: https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Genital Herpes treatment therapies with a considerable amount of success over the years.
• Genital Herpes companies working in the treatment market are Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, GlaxoSmithKline, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, and others, are developing therapies for the Genital Herpes treatment
• Emerging Genital Herpes therapies in the different phases of clinical trials are- mRNA 1608, Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, AIC-316 (pritelivir, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others are expected to have a significant impact on the Genital Herpes market in the coming years.
• In August 2022, An observational clinical research to identify the baseline traits of patients with recurrent symptomatic herpes simplex virus type 2 infection (HSV-2) has begun, according to Rational Vaccines Inc.
• In June 2020, The US FDA has designated pritelivir as a "breakthrough therapy" for the treatment of mucocutaneous HSV infections in immunocompromised patients.

Genital Herpes Overview
One of the most prevalent sexually transmitted illnesses is herpes genitalis. Herpes simplex virus type 2 (HSV-2) and, to a greater extent, herpes simplex virus type 1 (HSV-1) are the culprits. Both organisms are encapsulated DNA viruses that are susceptible to environmental influences and disinfectants.

Get a Free Sample PDF Report to know more about Genital Herpes Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Genital Herpes Drugs Under Different Phases of Clinical Development Include:
• mRNA 1608: Moderna Therapeutics
• Attenuated vaccine against HSV 1&2: Vaxxit
• HSV "Genital lesions" Skin cream/Lotion: Nanoviricides
• BNT 163: BioNTech
• GSK 3943104A: GlaxoSmithKline
• UB 621: United BioPharma
• HDIT101: Heidelberg ImmunoTherapeutics
• Pritelivir: AiCuris
• AIC-316 (pritelivir): AiCuris
• SIMPLIRIX (GSK208141): GlaxoSmithKline
• GEN-003: Genocea Biosciences
• HerpV (AG-707): Agenus
• VCL-HB01: Fresh Tracks Therapeutics
• SP-0148: Sanofi

Genital Herpes Route of Administration
Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Genital Herpes Molecule Type
Genital Herpes Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Genital Herpes Pipeline Therapeutics Assessment
• Genital Herpes Assessment by Product Type
• Genital Herpes By Stage and Product Type
• Genital Herpes Assessment by Route of Administration
• Genital Herpes By Stage and Route of Administration
• Genital Herpes Assessment by Molecule Type
• Genital Herpes by Stage and Molecule Type

DelveInsight's Genital Herpes Report covers around 28+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Genital Herpes product details are provided in the report. Download the Genital Herpes pipeline report to learn more about the emerging Genital Herpes therapies at:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Genital Herpes Therapeutics Market include:
Key companies developing therapies for Genital Herpes are - AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others.

Genital Herpes Pipeline Analysis:
The Genital Herpes pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Genital Herpes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Herpes Treatment.
• Genital Herpes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Genital Herpes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Genital Herpes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Genital Herpes drugs and therapies-
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Herpes Pipeline Market Drivers
• Increasing awareness among population regarding genital herpes infection, availability of high sensitivity and specificity of nucleic acid amplification based kits test type are some of the important factors that are fueling the Genital Herpes Market.

Genital Herpes Pipeline Market Barriers
• However, accessibility of diagnostic services, Insufficient R&D initiatives, pricing pressures, and stringent regulations, lack of novel strategies to prevent or suppress HSV-2 infection and other factors are creating obstacles in the Genital Herpes Market growth.

Scope of Genital Herpes Pipeline Drug Insight
• Coverage: Global
• Key Genital Herpes Companies: Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, GlaxoSmithKline, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, and others
• Key Genital Herpes Therapies: mRNA 1608, Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, AIC-316 (pritelivir, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others
• Genital Herpes Therapeutic Assessment: Genital Herpes current marketed and Genital Herpes emerging therapies
• Genital Herpes Market Dynamics: Genital Herpes market drivers and Genital Herpes market barriers

Request for Sample PDF Report for Genital Herpes Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Genital Herpes Report Introduction
2. Genital Herpes Executive Summary
3. Genital Herpes Overview
4. Genital Herpes- Analytical Perspective In-depth Commercial Assessment
5. Genital Herpes Pipeline Therapeutics
6. Genital Herpes Late Stage Products (Phase II/III)
7. Genital Herpes Mid Stage Products (Phase II)
8. Genital Herpes Early Stage Products (Phase I)
9. Genital Herpes Preclinical Stage Products
10. Genital Herpes Therapeutics Assessment
11. Genital Herpes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Genital Herpes Key Companies
14. Genital Herpes Key Products
15. Genital Herpes Unmet Needs
16 . Genital Herpes Market Drivers and Barriers
17. Genital Herpes Future Perspectives and Conclusion
18. Genital Herpes Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Genital Herpes Market https://www.delveinsight.com/report-store/genital-herpes-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Genital Herpes-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Genital Herpes Epidemiology https://www.delveinsight.com/report-store/genital-herpes-epidemiology?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Genital Herpes Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.